Hyungtai Sim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyungtai Sim has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Murim Choi
Seoul National University
3 shared publications - Bo Kyung Koo
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
1 shared publication - Byung-Hoon Lee
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea
1 shared publication - Deog Kyeom Kim
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea
1 shared publication Dong Gwang Kim
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea
1 shared publication- Dong Hyeon Lee
Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 24 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2272-2280.e10
Comprehensive Profiling of Genetic and Nongenetic Factors that Influence Skin Traits in Asian Women from 4 Countries
- 24 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2272-2280.e10
Open AccessComprehensive Profiling of Genetic and Nongenetic Factors that Influence Skin Traits in Asian Women from 4 Countries
- Open Access
- 6 December 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden
Clonal hematopoiesis of indeterminate potential (CHIP) allows estimation of clonal dynamics and documentation of somatic mutations in the hematopoietic system. Recent studies utilizing large cohorts of the general population and patients have revealed significant associations of CHIP burden with age and disease status, including in cancer and chronic diseases. An increasing number of cancer patients are treated with immune checkpoint inhibitors (ICIs), but the association of ICI response in non-small cell lung cancer (NSCLC) patients with CHIP burden remains to be determined. We collected blood samples from 100 metastatic NSCLC patients before and after ICI for high-depth sequencing of the CHIP panel and 63 samples for blood single-cell RNA sequencing. Whole exome sequencing was performed in an independent replication cohort of 180 patients. The impact of CHIP status on the immunotherapy response was not significant. However, metastatic lung cancer patients showed higher CHIP prevalence (44/100 for patients vs. 5/42 for controls; p = 0.01). In addition, lung squamous cell carcinoma (LUSC) patients showed increased burden of larger clones compared to lung adenocarcinoma (LUAD) patients (8/43 for LUSC vs. 2/50 for LUAD; p = 0.04). Furthermore, single-cell RNA-seq analysis of the matched patients showed significant enrichment of inflammatory pathways mediated by NF-κB in myeloid clusters of the severe CHIP group. Our findings suggest minimal involvement of CHIP mutation and clonal dynamics during immunotherapy but a possible role of CHIP as an indicator of immunologic response in NSCLC patients.
- 6 December 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessIncreased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden
Clonal hematopoiesis of indeterminate potential (CHIP) allows estimation of clonal dynamics and documentation of somatic mutations in the hematopoietic system. Recent studies utilizing large cohorts of the general population and patients have revealed significant associations of CHIP burden with age and disease status, including in cancer and chronic diseases. An increasing number of cancer patients are treated with immune checkpoint inhibitors (ICIs), but the association of ICI response in non-small cell lung cancer (NSCLC) patients with CHIP burden remains to be determined. We collected blood samples from 100 metastatic NSCLC patients before and after ICI for high-depth sequencing of the CHIP panel and 63 samples for blood single-cell RNA sequencing. Whole exome sequencing was performed in an independent replication cohort of 180 patients. The impact of CHIP status on the immunotherapy response was not significant. However, metastatic lung cancer patients showed higher CHIP prevalence (44/100 for patients vs. 5/42 for controls; p = 0.01). In addition, lung squamous cell carcinoma (LUSC) patients showed increased burden of larger clones compared to lung adenocarcinoma (LUAD) patients (8/43 for LUSC vs. 2/50 for LUAD; p = 0.04). Furthermore, single-cell RNA-seq analysis of the matched patients showed significant enrichment of inflammatory pathways mediated by NF-κB in myeloid clusters of the severe CHIP group. Our findings suggest minimal involvement of CHIP mutation and clonal dynamics during immunotherapy but a possible role of CHIP as an indicator of immunologic response in NSCLC patients.
- Open Access
- 25 May 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (1) , 139-149
Impact of Evolutionary Changes in Nonalcoholic Fatty Liver Disease on Lung Function Decline
Hyun Woo Lee, Goh Eun Chung, Bo Kyung Koo, Hyungtai Sim, Murim Choi, Dong Hyeon Lee, Seung Ho Choi, Soo Heon Kwak, Deog Kyeom Kim, and Won Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) consortium. Gut and Liver 2023;17:139-49. https://doi.org/10.5009/gnl210545
- 25 May 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (1) , 139-149
Open AccessImpact of Evolutionary Changes in Nonalcoholic Fatty Liver Disease on Lung Function Decline
Hyun Woo Lee, Goh Eun Chung, Bo Kyung Koo, Hyungtai Sim, Murim Choi, Dong Hyeon Lee, Seung Ho Choi, Soo Heon Kwak, Deog Kyeom Kim, and Won Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) consortium. Gut and Liver 2023;17:139-49. https://doi.org/10.5009/gnl210545
- Open Access
- 20 May 2019
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 35 (6) , 589
Correction to: Activation of SIRT1 by L-serine increases fatty acid oxidation and reverses insulin resistance in C2C12 myotubes
The original version of this article unfortunately contained a mistake in the article title.
- 20 May 2019
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 35 (6) , 589
Open AccessCorrection to: Activation of SIRT1 by L-serine increases fatty acid oxidation and reverses insulin resistance in C2C12 myotubes
The original version of this article unfortunately contained a mistake in the article title.